Assessment of patients with CTEPH
New and emerging data on medical therapies in CTEPH
Best practice in the management of CTEPH
Video Player Controls:
Prof. Joanna Pepke-Zaba discusses the current unmet needs in the management of patients with CTEPH and how new data may impact on practice.
Prof. Kim Kerr discusses the current unmet needs in the management of patients with CTEPH and how new data may impact on practice.
Prof. Hiromi Matsubara discusses the current unmet needs in the management of patients with CTEPH and how new data may impact on practice.
Please Select A Video:
Overview & Learning Objectives
In this activity, Prof. Joanna Pepke-Zaba reviews the latest data from CHEST 2020 and ERS 2020 on the use of medical therapy in CTEPH.
This activity has been jointly provided by Oakstone and touchIME. Oakstone Publishing is accredited by the ACCME to provide continuing medical education to physicians. read more
This activity has been designed to meet the educational needs of pulmonologists, cardiologists, cardiopulmonary surgeons, rheumatologists and other healthcare professionals involved in the multidisciplinary management of patients with CTEPH, globally.
Oakstone Publishing has assessed conflict of interest with its faculty, authors, editors, and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing’s planners, content reviewers, and editorial staff disclose no relevant commercial interests.
Prof. Joanna Pepke-Zaba discloses: Personal fees from Actelion, Bayer Pharmaceuticals and Merck.
Prof. Kim Kerr discloses: Grant/research fees from Bayer Pharmaceuticals.
Prof. Hiromi Matsubara discloses: Speaker fees from Actelion, Bayer Yakuhin and Nippon Shinyaku.
Walter Murray Yarbrough, MD, FACP, has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Director
Paul Taylor has no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
Oakstone Publishing designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to receive credit for this activity, participants must review and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AME). European physicians interested in converting 0.5 AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Date of original release: 16 December 2020. Date credits expire: 16 December 2021.
After watching this activity, participants should be better able to:
- Recall the new and emerging data around patient and disease characteristics in order to select the optimal treatment strategy for each individual patient
- Interpret new and emerging data for medical therapy and their impact on daily clinical practice
- Assess the latest changes to best practice for the care of patients with CTEPH